Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience

BMC Cancer

Rok Petric¹  Barbara Gazic²  Nikola Besic¹ 

[1] Department of Surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia

[2] Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

关键词: Pathology;    Survival;    Surgery;    Hürthle cell thyroid carcinoma;   

Others  :  1120963
DOI  :  10.1186/1471-2407-14-777

 received in 2014-06-19, accepted in 2014-10-17,  发布年份 2014

【 摘 要 】

Background

Hürthle cell thyroid carcinoma (HCTC) is a rare disease. It is believed that it is more aggressive than follicular thyroid carcinoma. The aim of our study was to identify factors associated with disease-specific and disease-free survival.

Methods

Altogether, 108 patients with HCTC (26 male, 82 female; median age 62 years; range 19–87 years) treated at our Institute from 1972 to 2011 were included in the present retrospective study. Data on age, clinical and histopathological factors, tumor stage, recurrence, disease-free and disease-specific survival were collected. Univariate analysis was used to identify factors associated with disease-specific survival. Cox’s multivariate regression model was used to identify independent prognostic factors for disease-specific survival.

Results

The follow-up period was 1 to 337 (median 105) months. Of 108 patients, 12 (11%) had distant and 8 (7%) had locoregional metastases before primary treatment. Recurrence was diagnosed in 26 cases (24%): locoregional, distant, and both locoregional and distant in 12, 11, and 3 cases, respectively. The 5-year, 10-year, and 20-year disease-specific survival were 96%, 88%, and 67%, respectively. Independent prognostic factors for disease-specific survival were: age of patients at diagnosis, distant metastases and residual tumor after surgery.

Conclusion

Long disease-specific survival was found in patients with HCTC younger than 45 years of age without distant metastases and without residual tumor after surgery.

【 授权许可】

   
2014 Petric et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kushchayeva Y, Duh Q-Y, Kebebew E, Clark OH: Prognostic indications for Hürthle cell cancer. World J Surg 2004, 28:1266-1270.
• [2]Bhattacharyya N: Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg 2003, 129:207-210.
• [3]Hedinger C, Williams ED, Sobin LH: The WHO histological classification of thyroid tumors: A commentary on the second edition. Cancer 1989, 63:908-911.
• [4]Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA: Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013, 98:E962-E972.
• [5]Kuo EJ, Roman SA, Sosa JA: Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery 2013, 154:1246-1254.
• [6]Goffredo P, Roman SA, Sosa JA: Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer 2013, 119:504-511.
• [7]Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH: Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery 2013, 154:1263-1271.
• [8]Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH: Hürthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974, 139:555-560.
• [9]Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF: Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 1984, 59:851-855.
• [10]Har-El G, Hadar T, Segal K, Levy R, Sidi J: Hurthle cell carcinoma of the thyroid gland: a tumor of moderate malignancy. Cancer 1986, 57:1613-1617.
• [11]Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J: Follicular Hürthle cell tumors of the thyroid gland. Cancer 1991, 68:1944-1953.
• [12]Caplan RH, Abellera RM, Kisken WA: Hürthle cell neoplasms of the thyroid gland: Reassessment of functional capacity. Thyroid 1994, 4:243-248.
• [13]McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J: Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 1996, 120:1000-1005.
• [14]Khafif A, Khafif RA, Attie JN: Hürthle cell carcinoma: a malignancy of low-grade potential. Head Neck 1999, 21:506-511.
• [15]Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP, Brennan MF, Shaha AR, Singh B: Hürthle cell carcinoma: a critical histopathological appraisal. J Clin Oncol 2001, 19:2616-2625.
• [16]Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K: Hürthle cell tumor of thyroid: Analysis of 188 cases. World J Surg 2001, 25:1160-1163.
• [17]Stojadinovic A, Hoos A, Ghossein RA, Urist MJ, Leung DH, Spiro RH, Shah JP, Brennan MF, Singh B, Shaha AR: Hürthle cell carcinoma: a 60-year experience. Ann Surg Oncol 2002, 9:197-203.
• [18]Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M: The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. Thyroid 2003, 13:577-584.
• [19]Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI: Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer 2003, 97:1186-1194.
• [20]Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL: Is there a role for radiation therapy in the management of Hürthle cell carcinoma? Int J Radiat Oncol Biol Phys 2003, 56:1067-1072.
• [21]Paunovic I, Krgovic K, Tatic S, Diklic A, Zivaljevic V, Kalezic N, Havelka M: Surgery for thyroid Hürthle cell tumours – a single institution experience. Eur J Surg Oncol 2006, 32:458-61.
• [22]Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B: Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer 2006, 106:1669-1676.
• [23]Mills SC, Haq M, Smellie WJ, Harmer C: Hürthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol 2009, 35:230-234.
• [24]Bishop JA, Wu G, Tufano RP, Westra WH: Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid 2012, 22:690-694.
• [25]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
• [26]Rosai J: Tumors of thyroid gland. In Atlas of Tumor Pathology. Edited by Rosai J, Carcangiu ML, DeLellis RA. Washington: Armed Forces Institute of Pathology; 1992:31-50.
• [27]LiVolsi VA, Baloch ZW: Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol 2004, 11:279-87.
• [28]Besic N, Hocevar M, Zgajnar J, Petric R, Pilko G: Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma. Thyroid 2006, 16:67-72.
• [29]Sobin LH, Gospodarowicz MK, Wittekind C: Thyroid gland (ICD-O C73). In TNM Classification of Malignant Tumours, 7th Edition. Edited by Sobin LH, Gospodarowicz MK, Witekind C. New York: Wiley Blackwell; 2009:58-62.
• [30]Schlumberger M, Pacini F: Follow up: Lessons from the past. In Thyroid Tumors. 2nd edition. Paris: Edicions Nucleon; 2003:147-165.
• [31]Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I: Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study. Thyroid 2012, 22:131-137.
• [32]Zagar I, Schwarzbartl-Pevec A, Vidergar-Kralj B, Horvat R, Besic N: Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinoma. J Thyroid Res 2012, 2012:670180.
• [33]Besic N, Zgajnar J, Hocevar M, Frkovic-Grazio S: Is patient’s age a prognostic factor for follicular thyroid carcinoma in the TNM classification system? Thyroid 2005, 15:439-448.